The longevity field has reached an inflection point. After decades of promising animal studies, senolytic therapies — drugs that selectively eliminate senescent cells — are entering rigorous human trials. Early data suggests they may lower epigenetic age markers, improve mobility, and enhance cognitive function.
This matters for enhancement as much as it matters for medicine.
The Senescence Problem
Senescent cells are biological debris. Once functioning normally, they’ve entered a state of permanent growth arrest — no longer dividing, no longer contributing, but refusing to die. They accumulate with age, secreting inflammatory factors that damage surrounding tissue and accelerate aging throughout the body.
Think of them as employees who’ve stopped working but won’t leave. They take up space. They complain constantly. They make everyone around them worse at their jobs.
Eliminating them restores function.
What the Data Shows
The dasatinib-quercetin combination has emerged as the most thoroughly characterized senolytic protocol in human trials. Originally repurposed from cancer treatment, this combination selectively triggers apoptosis in senescent cells while leaving healthy cells intact.
Recent findings are encouraging: fisetin, a natural flavonoid, appears to preserve muscle mass and strength by flushing senescent cells. SGLT2 inhibitors — drugs originally developed for diabetes — have shown unexpected effects on telomere length, suggesting they may modulate multiple hallmarks of aging simultaneously.
The multi-target approach is proving essential. Aging isn’t caused by a single mechanism, and neither can it be addressed by a single intervention.
Implications for Enhancement
At Unzyme Laboratories, we’ve integrated senolytic protocols into our long-term volunteer monitoring program for three years. Our interest is specific: enhanced individuals may experience accelerated cellular turnover due to increased metabolic demands. This could theoretically produce higher rates of senescent cell accumulation.
Our data neither confirms nor refutes this hypothesis conclusively. What we can say: volunteers receiving periodic senolytic interventions report sustained enhancement performance at Year 5 that matches or exceeds Year 1 baselines. Control cohorts show gradual performance degradation consistent with normal aging.
Senolytics appear to extend the longevity of enhancement itself.
The Rejuvenation Horizon
Clearing senescent cells is defensive — removing what harms us. The next frontier is offensive: actively rejuvenating aged tissues to youthful states.
Partial epigenetic reprogramming offers this possibility. By transiently expressing Yamanaka factors — the genes that can transform adult cells back into stem cells — researchers have demonstrated age reversal in animal models. Cells become biologically younger. Tissues regenerate. Function returns.
Elysium Health’s ER-100 is expected to enter human trials this year. If successful, it would represent the first genuine rejuvenation therapy — not slowing aging, not preventing damage, but reversing the clock.
Our Position
Unzyme Laboratories views longevity not as a separate field but as integral to enhancement. What value is enhanced cognition if the brain degrades within decades? What use is optimized physiology if the body fails?
We enhance for the long term. This requires maintaining the substrate — the biological foundation — that enhancement builds upon.
Our enhancement protocols increasingly incorporate longevity interventions as standard practice. Senolytic cycling. Telomere monitoring. Epigenetic age testing at regular intervals. We optimize not just for peak performance but for performance duration.
The $120 Billion Question
The global anti-aging market is projected to approach $120 billion by 2030. This represents extraordinary commercial interest — and extraordinary risk of overpromising.
We urge caution in evaluating longevity claims. Much of what’s marketed as “anti-aging” is cosmetic at best, fraudulent at worst. Genuine interventions that modulate the biology of aging are emerging, but they remain the exception.
Unzyme Laboratories publishes our longevity protocols and outcome data in peer-reviewed journals. We welcome scrutiny. We encourage other enhancement organizations to do the same.
The future of human enhancement depends on extending human healthspan. We must get this right.
Dr. Yuki Tanaka leads Neural Enhancement Research at Unzyme Laboratories.